Cell salvage using the continuous autotransfusion device CATSmart – an observational bicenter technical evaluation

Lindau, Simone; Kohlhaas, Madeline; Nosch, M.; Choorapoikayil, Suma; Zacharowski, Kai; Meybohm, Patrick

doi:10.1186/s12871-018-0651-0

Cited by 9 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mansour et al 15.2%; P < 0.001; fig. 4A) during the second cycle in the pretreated and posttreated blood, respectively.…”

Section: Perioperative Medicinementioning

confidence: 92%

“…Blood units were diluted in normal saline (0.9% NaCl; Macopharma, France) up to 1,200 ml (including 200 ml of collection reservoir priming) to obtain clinically relevant hematocrits of 14.4% (13.1 to 15.3%), corresponding to initial hematocrits measured in blood collection reservoir during cardiac and orthopedic surgeries (ranging between 10 and 20%) while preserving between-subject heterogeneity. 7,[15][16][17] A high concentration of unfractionated heparin (Choay heparin; Sanofi-Aventis, France) was added to whole blood before dilution in saline (fig. 1); the final concentration of heparin in the collection reservoir was 12 IU/ml, to evaluate heparin washout in worst-case clinical conditions.…”

Section: Perioperative Medicinementioning

confidence: 99%

See 1 more Smart Citation

Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device

et al. 2021

View full text Add to dashboard Cite

Background The SAME device (i-SEP, France) is an innovative filtration-based autotransfusion device able to salvage and wash both red blood cells and platelets. This study evaluated the device performances using human whole blood with the hypothesis that the device will be able to salvage platelets while achieving a erythrocyte yield of 80% and removal ratios of 90% for heparin and 80% for major plasma proteins without inducing signification activation of salvaged cells. Methods Thirty healthy human whole blood units (median volume, 478 ml) were diluted, heparinized, and processed by the device in two consecutive treatment cycles. Samples from the collection reservoir and the concentrated blood were analyzed. Complete blood count was performed to measure blood cell recovery rates. Flow cytometry evaluated the activation state and function of platelets and leukocytes. Heparin and plasma proteins were measured to assess washing performance. Results The global erythrocyte yield was 88.1% (84.1 to 91.1%; median [25th to 75th]) with posttreatment hematocrits of 48.9% (44.8 to 51.4%) and 51.4% (48.4 to 53.2%) for the first and second cycles, respectively. Ektacytometry did not show evidence of erythrocyte alteration. Platelet recovery was 36.8% (26.3 to 43.4%), with posttreatment counts of 88 × 109/l (73 to 101 × 109/l) and 115 × 109/l (95 to 135 × 109/l) for the first and second cycles, respectively. Recovered platelets showed a low basal P-selectin expression at 10.8% (8.1 to 15.2%) and a strong response to thrombin-activating peptide. Leukocyte yield was 93.0% (90.1 to 95.7%) with no activation or cell death. Global removal ratios were 98.3% (97.8 to 98.9%), 98.2% (96.9 to 98.8%), and 88.3% (86.6 to 90.7%) for heparin, albumin, and fibrinogen, respectively. The processing times were 4.4 min (4.2 to 4.6 min) and 4.4 min (4.2 to 4.7 min) for the first and second cycles, respectively. Conclusions This study demonstrated the performance of the SAME device. Platelets and red blood cells were salvaged without significant impact on cell integrity and function. In the meantime, leukocytes were not activated, and the washing quality of the device prevented reinfusion of high concentrations of heparin and plasma proteins. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New

show abstract

“…Mansour et al 15.2%; P < 0.001; fig. 4A) during the second cycle in the pretreated and posttreated blood, respectively.…”

Section: Perioperative Medicinementioning

confidence: 92%

Section: Perioperative Medicinementioning

confidence: 99%

Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 18 Centrifugal technology has been shown to effectively reduce the non-cellular load by about 90%. 8 , 19 , 20 The centrifugal autoLog ® procedure resulted in a removal of 98% of the total protein level. The reduction of smaller solutes was less effective, with about 20% of the small-molecule glucose and ion potassium left in the concentrated red cell product.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Washing Efficiency and Recovery of Blood Cells Between Centrifugation, Coarse Filtration and Microfiltration Techniques to Prepare Autologous Blood for Transfusion

Amenge¹,

Scherphof²,

Osemwengie³

et al. 2022

JBM

View full text Add to dashboard Cite

Purpose Cell salvage is the process by which blood lost in surgery is collected and washed or filtered to produce autologous blood for re-transfusion to the patient. Cell salvage aims to reduce the need for donor blood. Centrifugal cell salvage washing technique is a preferred medical treatment in order to retain lost red blood cells (RBCs) without contaminants. Although this technology very efficiently collects and washes shed blood, it is costly and often impractical or unavailable, especially in middle- or low-income countries. This study assessed two innovative filter devices as an alternative to centrifugal cell salvage technology: a coarse collection filter device (Hemafuse) and a microfiltration device (HemoClear). In contrast to centrifugal technology, both filter devices do not require electricity, nor costly equipment and extensive training. We compared the effectiveness of these filtration technologies to remove plasma constituents and recover and concentrate the cellular components with centrifugal technology (autoLog ® device). Methods Whole blood was processed with each technology according to the device manufacturer’s instructions. Before and after processing, the blood products were analyzed for supernatant solutes and cellular composition. Results The centrifugal technology confirmed its efficacy to remove potentially harmful solutes and capture red blood cells. The microfiltration technology (HemoClear) reached comparable levels of removal of solutes, with a potential advantage over centrifugal technology in the ability to also recover platelets. The coarse filtration technology (Hemafuse) had no washing capacity but, like the microfiltration technology, has the advantage of recovering platelets. Conclusion Innovative filtration devices represent an alternative to centrifugal technology in the preparation of autologous blood for reinfusion. The HemoClear technology for the first time enables the recovery of washed platelets and red blood cells. Clinical trials will have to be performed to investigate the clinical value of this new autologous blood product.

show abstract

“…Оправданно это или нет, будущее покажет. Во всяком случае, качество реинфузата существенно не ухудшилось [11,12].…”

Section: современные селл-сейверыunclassified

Blood reinfusion in surgery. State of art. Review

Lubnin

Gromova

2019

Annals of Critical Care

View full text Add to dashboard Cite

В работе на основании данных литературы и собственного опыта анализируется современное состояние проблемы реинфузии крови в хирургии. Рассмотрены технические решения, методические подходы, аппаратура для проведения реинфузии крови у хирургических больных. Также рассмотрены такие аспекты проблемы, как показания, противопоказания и особенности применения методики в различных областях хирургии. Ключевые слова: реинфузия крови в хирургии, технические решения, показания и противопоказания, возможные осложнения u Для корреспонденции: Лубнин Андрей Юрьевичд-р мед. наук, профессор, руководитель отдела анестезиологии, реанимации и интенсивной терапии ФГАУ «НМИЦ нейрохирургии им. акад. Н.Н. Бурденко» МЗ РФ,

show abstract

Cell salvage using the continuous autotransfusion device CATSmart – an observational bicenter technical evaluation

Cited by 9 publications

References 9 publications

Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device

Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device

Comparison of Washing Efficiency and Recovery of Blood Cells Between Centrifugation, Coarse Filtration and Microfiltration Techniques to Prepare Autologous Blood for Transfusion

Blood reinfusion in surgery. State of art. Review

Contact Info

Product

Resources

About